SCHEMBL3305686

SCHEMBL3305686

c1ccc(N(CCN(c2ccccc2)P(c2ccccc2)c2ccccc2)P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
KMT2A Q03164 3/20 0.31
MEN1 O00255 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ALDH1A1 P00352 4/20 0.31
NPSR1 Q6W5P4 2/20 0.31
ALOX15 P16050 1/20 0.31
HTT P42858 3/20 0.31
TP53 P04637 1/20 0.31
KCNH2 Q12809 1/20 0.31
TSHR P16473 2/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
RAB9A P51151 1/20 0.30
GLA P06280 1/20 0.30
KDM4E B2RXH2 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11729095 0.82 TSHR (0.41) CYP3A4TDP1KMT2AMEN1CYP2C9
SCHEMBL6573773 0.81 ALDH1A1 (0.44) ALDH1A1KCNH2MAPTL3MBTL1
SCHEMBL11722993 0.74 CYP2C19 (0.39) TDP1KMT2AMEN1CYP2C19SMN1; SMN2
SCHEMBL16755617 0.72 TDP1 (0.43) CYP3A4TDP1KMT2AMEN1CYP2C9
SCHEMBL19530997 0.72 CYP3A4 (0.43) CYP3A4TDP1KDM4EESR1ESR2
SCHEMBL2576486 0.72 TDP1 (0.43) CYP3A4TDP1KMT2AMEN1CYP2C9
SCHEMBL2574194 0.70 MEN1 (0.42) CYP3A4TDP1KMT2AMEN1ALDH1A1
SCHEMBL14271678 0.68 TAAR1 (0.39) CYP3A4TDP1KMT2AALDH1A1TSHR
SCHEMBL28635021 0.68 TDP1 (0.50) CYP3A4TDP1ALDH1A1TSHRGLA
SCHEMBL14938874 0.67 TDP1 (0.38) CYP3A4TDP1KMT2AMEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099898-A1 Processes and Intermediates For Preparing Benzyle Epoxides ELAN PHARMACEUTICALS, INC. 2010-04-22 US disclosed
EP-1381597-B1 PROCESS FOR PREPARING HYDROXYETHYLAMINES ELAN PHARM INC (US) 2008-07-16 EP disclosed
EP-1395551-B1 HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES ELAN PHARM INC (US) 2008-05-21 EP disclosed
US-20080096942-A1 Substituted Hydroxyethylamines ELAN PHARMACEUTICALS, INC. 2008-04-24 US disclosed
US-7351849-B2 Process for producing optically active β-amino acid derivatives TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-04-01 US disclosed
US-20070299263-A1 Hydroxy Alkyl Amines Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company 2007-12-27 US disclosed
US-7312360-B2 Substituted hydroxyethylamines ELAN PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
US-7144897-B2 Hydroxy alkyl amines Elan Oharmaceuticals, Inc. (US) 2006-12-05 US disclosed
US-20060205968-A1 Process for producing optically active beta-amino acid derivatives TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-09-14 US disclosed
US-6849750-B2 Processes and intermediates for preparing benzyl epoxides PHARMACIA & UPJOHN COMPANY LLC (US) 2005-02-01 US disclosed
US-20040044072-A1 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
US-20030166717-A1 Hydroxy alkyl amines FRESKOS JOHN (US) 2003-09-04 US disclosed
US-20030004360-A1 Processes and intermediates for preparing benzyl epoxides PHARMACIA & UPJOHN COMPANY 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096942-A1 Substituted Hydroxyethylamines BACE1, BACE2, MME CYP3A4 584/4885TDP1 400/4885KMT2A 528/4885
US-20030166717-A1 Hydroxy alkyl amines PSEN1, MAOA, PSEN2 CYP3A4 879/4885TDP1 189/4885KMT2A 1368/4885
US-20040044072-A1 Substituted hydroxyethylamines BACE1, BACE2, PSEN1 CYP3A4 737/4885TDP1 257/4885KMT2A 704/4885
US-20100099898-A1 Processes and Intermediates For Preparing Benzyle Epoxides VKORC1, EPOR, POR CYP3A4 35/4885TDP1 3959/4885KMT2A 4391/4885
US-20030004360-A1 Processes and intermediates for preparing benzyl epoxides CYP2F1, VKORC1, VKORC1L1 CYP3A4 14/4885TDP1 3808/4885KMT2A 4509/4885
US-20060205968-A1 Process for producing optically active beta-amino acid derivatives BCAT1, ALAD, AADAT CYP3A4 1790/4885TDP1 4754/4885KMT2A 2991/4885
US-20070299263-A1 Hydroxy Alkyl Amines MAOA, PSEN2, PSEN1 CYP3A4 936/4885TDP1 428/4885KMT2A 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.